河北大学学报(哲学社会科学版) ›› 2016, Vol. 41 ›› Issue (6): 133-137.DOI: 10.3969/j.issn.1005-6378.2016.06.020

• 论著 • 上一篇    下一篇

关于构建我国药品管制行政公益诉讼制度的探讨

曹海晶,康希   

  1. 华中科技大学 法学院,湖北 武汉430074
  • 收稿日期:2016-08-20 修回日期:2017-02-16 出版日期:2016-11-25 发布日期:2016-11-25
  • 作者简介:曹海晶(1957—),女,湖北武汉人,华中科技大学法学院教授、博士研究生导师,主要研究方向:宪法学和行政法。

Exploration on the Establishment of a Public Administrative Litigation System for Pharmaceutical Control in China

CAO Hai jing,KANG Xi   

  1. Law School,Huazhong University of Science and Technology,Wuhan,Hubei 430074,China
  • Received:2016-08-20 Revised:2017-02-16 Online:2016-11-25 Published:2016-11-25

摘要: 随着依法治国与依法行政的实质性开展,公民法制观念不断增强,对于权益的保护意识逐步从私益向公益延伸。近年来药品安全事件频发,传统侵权损害诉讼模式已经无法满足公益保障需求,为避免药品管制过程中行政权力滥用与不作为情况的发生,药品管制行政公益诉讼制度的建立几成定局。基于此,应当依托当前修改行政诉讼法的大背景,以药品管制行政公益诉讼制度为研究对象,对原告主体资格认定、制度模式、举证责任以及奖惩措施等问题提出具体设计。

关键词: 公共利益, 药品管制, 行政公益诉讼

Abstract: With the substantive development governing the country by law and administration by law in China,the awareness of citizens has been increasingly enhanced and their awareness of interest protection has been extended from the private interest to the public interest.Recently,a great number of accidents concerning drug safety took place in China and traditional ligation modes are not adequate to meet the demand of public interest protection.To avoid the abuse and inaction of administrative power,the establishment of a public administrative litigation system for pharmaceutical control in China has become inevitable.In view of this development,on the basis amendment of administrative litigation law,we examined the public administrative litigation system for pharmaceutical control and proposed some suggestions concerning the qualification recognition of plaintiff,system modes,burden of proof,rewards and punishment and other issues.

Key words: public interest, pharmaceutical control, public administrative litigation

中图分类号: